A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2018
At a glance
- Drugs Canakinumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Jul 2018 Planned End Date changed from 1 Dec 2023 to 15 Sep 2025.
- 17 Jul 2018 Planned primary completion date changed from 1 Mar 2022 to 29 Oct 2021.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.